Key result
Ex vivo treatment with ASA, 2MeSAMP, MRS 2179, or combined 2MeSAMP and MRS 2179 decreased total platelet accumulation by 27.5%, 75.6%, 77.7%, and 87.9%, respectively.
Why the study?
Does ex vivo treatment with COX-1, P2Y1, and P2Y12 inhibitors reduce platelet accumulation in a whole blood microfluidic flow assay?
Does ex vivo treatment with COX-1, P2Y1, and P2Y12 inhibitors reduce platelet accumulation in a whole blood microfluidic flow assay?
Microfluidic devices can effectively detect platelet sensitivity to various antiplatelet agents using a self-normalized metric (R-value) from a single blood sample.
Answers are grounded in this paper and cite their sources.
Ex vivo reductions in microfluidic platelet accumulation support assay refinement; leaves open translation to in vivo or clinical settings.
BACKGROUND: Microfluidic devices recreate the hemodynamic conditions of thrombosis. METHODS: Whole blood inhibited with PPACK was treated ex vivo with inhibitors and perfused over collagen for 300 s (wall shear rate=200 s(-1)) using a microfluidic flow assay. Platelet accumulation was measured in the presence of COX-1 inhibitor (aspirin, ASA), P2Y₁ inhibitor (MRS 2179), P2Y₁₂ inhibitor (2MeSAMP) or combined P2Y1 and P2Y₁₂ inhibitors. RESULTS: High dose ASA (500 μM), 2MeSAMP (100 μM), MRS 2179 (10 μM), or combined 2MeSAMP and MRS 2179 decreased total platelet accumulation by 27.5%, 75.6%, 77.7%, and 87.9% (p<0.01), respectively. ASA reduced secondary aggregation rate between 150 and 300 s without effect on primary deposition rate on collagen from 60 to 150 s. In contrast, 2MeSAMP and MRS 2179 acted earlier and reduced primary deposition to collagen between 60 and 105 s and secondary aggregation between 105 and 300 s. R(COX) and R(P2Y) (defined as a ratio of secondary aggregation rate to primary deposition rate) demonstrated 9 of 10 subjects had R(COX)<1 or R(P2Y)<1 following ASA or 2MeSAMP addition, while 6 of 10 subjects had R(P2Y)<1 following MRS 2179 addition. Combined MRS 2179 and 2MeSAMP inhibited primary platelet deposition rate and platelet secondary aggregation beyond that of each individual inhibitor. Receiver-Operator Characteristic area under the curve (AUC) indicated the robustness of R(COX) and R(P2Y) to detect inhibition of secondary platelet aggregation by ASA, 2MeSAMP, and MRS 2179 (AUC of 0.874 0.966, and 0.889, respectively). CONCLUSIONS: Microfluidic devices can detect platelet sensitivity to antiplatelet agents. The R-value can serve as a self-normalized metric of platelet function for a single blood sample.
No takes yet. Share an insight, caveat, or question.
Li et al. (2013) studied this question. COX-1, P2Y1, and P2Y12 inhibitors (ASA, MRS 2179, 2MeSAMP) was evaluated on Total platelet accumulation (p=<0.01). Ex vivo treatment with ASA, 2MeSAMP, MRS 2179, or combined 2MeSAMP and MRS 2179 decreased total platelet accumulation by 27.5%, 75.6%, 77.7%, and 87.9%, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: